Monoclonal antibodies are shown to be safe and effective in patients with dyslipidaemiaBMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h2251 (Published 28 April 2015) Cite this as: BMJ 2015;350:h2251
- Jacqui Wise
A new class of cholesterol drug, PCSK9 inhibitors, can reduce mortality and significantly reduce low density lipoprotein (LDL) cholesterol and lipoprotein in patients with hypercholesterolaemia, a meta-analysis published in the Annals of Internal Medicine has found.1
A sizeable proportion of patients treated with statins do not achieve the recommended target LDL cholesterol levels, and some discontinue treatment owing to drug related side effects. In the past five years many monoclonal antibodies, including evolocumab, alirocumab, and bococizumab, have been developed as PCSK9 inhibitors that disrupt the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial